Medicare AdvantageCoverageMedium impact
MA06.001f, Apheresis Therapy
Independence Blue Cross·Hematology, Nephrology, Oncology·Medical Policy
Effective date
Jul 9, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA06.001f for Apheresis Therapy has been reissued and will take effect on July 9, 2025. This is a policy update that may affect coverage criteria, billing requirements, or documentation standards for apheresis procedures under Medicare Advantage plans.
Action Required
Before July 9, 2025: Billing team must review the complete MA06.001f Apheresis Therapy policy at the provided URL to identify specific changes to coverage criteria, prior authorization requirements, or billing guidelines. Update billing software and encounter forms based on policy requirements. Notify providers who perform apheresis procedures of any new documentation or coverage requirements.